EWnFM: An Environment States Oriented Web Service Non-Functional Property Model

A proper model of Web service non-functional properties is the key foundation to the evaluation of non-functional properties of Adaptive Service Based Software (ASBS) systems. As the environment in which a Web service is deployed may keep changing, environmental factors would affect the non-functional properties of a Web service a lot. However, available non-functional property models usually ignore the impact of environmental factors, leading to insufficient modeling power of non-functional properties, limited effect of system wide non-functional property evaluation based on these models, and the inability to support environment states oriented specifications of ASBS. This paper propose an environment states oriented Web service non-functional property model. By considering the differences of a non-functional property under different environment states, environment states of a Web service is analyzed using a Dirichlet process based method. With such a foundation, an environment states oriented Web service non-functional property model is introduced, together with the parameter estimation methods based on historical monitor data. Experiment results have shown that compared to the evaluated methods, our model could generate data that are much close to real monitored data

Vasohibin 2 Decreases the Cisplatin Sensitivity of Hepatocarcinoma Cell Line by Downregulating p53

<div><p>Hepatocellular carcinoma (HCC) is a prevalent problem worldwide. Chemotherapy, especially cisplatin (CDDP)-based systemic chemotherapy, is the best option for advanced liver cancer. However, CDDP resistance is becoming common and hindering the clinical application of CDDP. Meanwhile, no consensus has been reached regarding the chemotherapeutic use of vasohibin 2 (VASH2), which promotes the angiogenesis and proliferation of cancer cells. In this work, a tissue microarray was used to observe VASH2 and its possible role in cancer treatment. Results showed that VASH2 was highly expressed in HCC tissues and was significantly correlated with cancer differentiation. To further investigate the efficacy and mechanism of the combination of VASH2 with anti-cancer drugs in liver cancer cells, we stably built VASH2 overexpression and knockdown cell lines. We found that VASH2 can influence the CDDP sensitivity and that the cell overexpression of VASH2 had a higher cell viability and lower apoptosis rate after CDDP exposure. We also observed that VASH2 overexpression downregulated wild-type p53, as well as suppressed the expression of the pro-apoptotic protein BCL2-associated X protein (Bax) and cleaved caspase-3 (CC-3) after treatment by CDDP. Conversely, the knockdown of VASH2 significantly inhibited these effects. In an <i>in vivo</i> chemosensitivity study, nude mice were subcutaneously injected with tumor cells and received CDDP treatment through intraperitoneal administration every 3 days. We found that VASH2 knockdown markedly limited the tumor growth and enhanced the CDDP toxicity and apoptosis of tumor cells. Western blot analysis revealed that tumor cells with downregulated VASH2 had a higher expression of wild-type p53, Bax, and CC-3 than control cells. Overall, our results indicated the novel roles of VASH2 in the chemoresistance of hepatocarcinoma cells to CDDP and suggested that VASH2 may be a promising anticancer target.</p></div

Expression of VASH2 in tissues.

<p>IHC analysis of VASH2 in human normal liver tissue (A) and human liver cancer tissue (B–D) at 20× magnification. In (A), we did not observed VASH2 protein in the cytoplasm. (B) The level of VASH2 protein localized in the cytoplasm was weakly stained. (C) The cytoplasm was moderately stained. (D) Strong staining was observed.</p

Patient Demographic Features.

<p>*The grade 1-3 in Pathology Diagnosis is equivalent to well-differentiated, moderately-differentiated or poorly-differentiated, respectively, under microscope.</p

Knockdown of VASH2 enhanced the apoptosis of tumor cells by CDDP treatment.

<p>(A and B) TUNEL analysis showing enhanced apoptosis rate in tumor cells when the HepG2-shVASH2 group was compared with the HepG2-shcont group (<i>P</i><0.05). However, no statistical difference was found in HepG2-VASH2 vs. HepG2-EGFP (<i>P</i>>0.05) at 40× magnification. (C) Western blot analysis showed that p53, Bax, and CC-3 were highly expressed in the HepG2-shVSAH2 group.</p

VASH2 influenced the sensitivity of tumor cells to CDDP <i>in vivo</i>.

<p>HepG2-VASH2, HepG2-EGFP, HepG2-shVASH2, or HepG2-shcont cells were suspended at a density of 10⁷ cells/ml, and 100 µl was injected into the flank of nude mice (n  =  9). On day 9, mice in CDDP(+) group were given CDDP (10 mg/kg) intraperitoneally every 3 days. After six 3-day cycles of treatment, all nude mice were sacrificed, and tumors were excised from nude mice. (A) The HepG2-shVASH2 tumors were smaller than those of the HepG2-shcont groups, whereas the size of the HepG2-VASH2 tumors did not significantly differ from that of HepG2-EGFP tumors. (B) Tumor growth curves. Tumor volume was calculated 3 days after the first treatment with CDDP using the formula (<i>W</i>²×<i>L</i>)/2 every 3 days. The data are presented as the mean ± SD of nine tumors per group. *A significant difference was found between the HepG2-shVASH2 and HepG2-shcont groups (<i>P</i><0.05). (C) The comparison of tumor volume between CDDP(+) group and CDDP(−) group(*<i>P</i><0.05). (D and E) Total RNA and protein were extracted from CDDP(+) group randomly, and VASH2 expression was measured by qRT-PCR and Western blot analyses.</p